Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2000019999) FULVIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS CONDITIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2000/019999 International Application No.: PCT/IB1999/001649
Publication Date: 13.04.2000 International Filing Date: 08.10.1999
Chapter 2 Demand Filed: 08.05.2000
IPC:
A61K 31/352 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
352
condensed with carbocyclic rings, e.g. cannabinols, methantheline
Applicants:
ENERKOM (PROPRIETARY) LIMITED [ZA/ZA]; Building 46F Csir 0001 Pretoria, ZA (AllExceptUS)
DEKKER, Johannes [ZA/ZA]; ZA (UsOnly)
MEDLEN, Constance, Elizabeth [ZA/ZA]; ZA (UsOnly)
Inventors:
DEKKER, Johannes; ZA
MEDLEN, Constance, Elizabeth; ZA
Agent:
GILSON, David, Grant; Spoor and Fisher Rochester Place, 173 Rivonia Road Morningside, Sandton P.O. Box 41312 2024 Craighall, ZA
Priority Data:
98/919008.10.1998ZA
99/284821.04.1999ZA
Title (EN) FULVIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS CONDITIONS
(FR) ACIDE FULVIQUE ET UTILISATION DE CELUI-CI POUR LE TRAITEMENT DE DIVERS ETATS PATHOLOGIQUES
Abstract:
(EN) A pharmaceutical composition comprising a fulvic acid, salt, ester or derivative thereof as an active ingredient is disclosed. The composition is preferably administered orally or topically for treating a condition in a human or an animal. The condition may, for example, be inflammation, acne, eczema or bacterial or fungal or viral infections.
(FR) Cette invention a trait à une composition pharmaceutique contenant de l'acide fulvique, un ester ou un dérivé de cet acide, en tant qu'ingrédient actif. On administre cette composition, de préférence, par voie orale ou localement, pour traiter un état pathologique donné chez un humain ou un animal. Cet état pathologique peut être, par exemple, une inflammation, de l'acné, un eczéma ou des infections bactériennes, fongiques ou virales.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1126837EP1698333EP1700599EP1700600US6569900JP4700808
JP2002526407 AU1999059923